Human sC5b-9(Soluble Terminal Complement Complex C5b-9) ELISA Kit
中文名称：人可溶性末端补体复合物sC5b-9(sC5b-9)酶联免疫吸附测定试剂盒
Price:
- 反应性： Human
- 检测范围： 31.25-2000 ng/mL
- 灵敏度： 18.75 ng/mL
| 产品应用 | ELISA |
| 检测原理 | 本试剂盒采用双抗体夹心ELISA法。用抗人sC5b-9抗体包被于酶标板上，实验时样品（或标准品）中的人sC5b-9会与包被抗体结合。后依次加入生物素化的抗人sC5b-9抗体和辣根过氧化物酶标记的亲和素，抗人sC5b-9抗体与结合在包被抗体上的人sC5b-9结合，生物素与亲和素特异性结合而形成免疫复合物，游离的成分被洗去。加入显色底物(TMB)，TMB在辣根过氧化物酶的催化下呈现蓝色，加终止液后变成黄色。用酶标仪在450 nm波长处测OD值，sC5b-9浓度与OD450值之间呈正比，通过绘制标准曲线计算出样品中sC5b-9的浓度。 |
| 反应类型 | Sandwich-ELISA |
| 规格 |
96 T
/ 48 T
/ 96 T × 5
|
| 反应时间 | 3 h 30 min |
| 反应性 | Human |
| 检测方法 | 比色法;ELISA;夹心法 |
| 检测范围 | 31.25-2000 ng/mL |
| 灵敏度 | 18.75 ng/mL |
| 样本体积 | 100 μL |
| 样本类型 | 血清、血浆或其他生物体液 |
| 特异性 | 可检测样本中的人sC5b-9，且与其它类似物无明显交叉反应 |
| 精密度 | 板内，板间变异系数均<10% |
| 回收率 | 80%-120% |
| 储存条件 | 2-8℃ |
| 有效期 | 12个月 |
| 数据处理 |
-
Predictive value of soluble CD59 for poor 28-day neurological prognosis and all-cause mortality in patients after cardiopulmonary resuscitation: a prospective observatory study
IF: 7.100 -
Hepatitis B virus suppresses complement C9 synthesis by limiting the availability of transcription factor USF-1 and inhibits formation of membrane attack complex: implications in disease pathogenesis
IF: 12.771 -
Recruitment of IL-1β-producing intermediate monocytes enhanced by C5a contributes to the development of malignant pleural effusion
IF: 3.223Journal： Thoracic Cancer (2022)Reactivity：HumanSample Type：pleural effusion -
Post-COVID-19 Patients Who Develop Lung Fibrotic-like Changes Have Lower Circulating Levels of IFN-β but Higher Levels of IL-1α and TGF-β
IF: 6.081 -
Elevated complement mediator levels in endothelial-derived plasma exosomes implicate endothelial innate inflammation in diminished brain function of aging humans
IF: 4.380 -
Altered levels of complement components associated with non-immediate drug hypersensitivity reactions
IF: 1.734 -
High complement levels in astrocyte-derived exosomes of Alzheimer disease
IF: 10.250
实验操作视频
